ABSTRACT
In patients with chronic heart failure (CHF), anemia is associated with more severe symptoms and worse prognosis. Erythropoiesis-stimulating proteins (ESPs) increase hemoglobin and may be of therapeutic benefit. We investigated the pharmacokinetics and pharmacodynamics of the long-acting ESP, darbepoetin alfa, administered on 2 occasions 1 month apart to 30 healthy subjects and 33 patients with symptomatic CHF and anemia (hemoglobinSubject(s)
Anemia/drug therapy
, Cardiac Output, Low/drug therapy
, Erythropoietin/analogs & derivatives
, Aged
, Anemia/blood
, Anemia/complications
, Biological Availability
, Cardiac Output, Low/blood
, Cardiac Output, Low/complications
, Chronic Disease
, Cross-Over Studies
, Darbepoetin alfa
, Double-Blind Method
, Drug Administration Schedule
, Erythropoietin/administration & dosage
, Erythropoietin/pharmacokinetics
, Erythropoietin/pharmacology
, Erythropoietin/therapeutic use
, Female
, Hemoglobins/analysis
, Humans
, Injections, Intravenous
, Injections, Subcutaneous
, Male
, Middle Aged
